
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Focal segmental glomerulosclerosis pathophysiology
Introduction
Overview
Overview
The pathophysiology of focal segmental glomerulosclerosis (FSGS) is based on two types of FSGS. Primary FSGS is also known as idiopathic FSGS, there is a hypothesis that suggests it occurs as a result of circulating immune activating factors interacting with the glomerular epithelium. The underlying pathogenesis of FSGS is fusion or effacement of the foot processes (podocytes) of the glomeruli and sclerosing of some parts of the glomeruli. These changes result in apoptosis and detachment of the glomerular basement membrane (GBM) resulting in subsequent loss of negative charge on podocytes and podocytopenia. Secondary FSGS is based on glomerular hypertrophy and hyperfiltration and over expression of inflammatory mediators such as, TGF-beta, PDGF and VEGF. The underlying pathogenesis can be based on multiple genetic mutations in NPHS1, NEPH1, NPHS2, WT1 and INF2 genes. Conditions associated with FSGS include, diabetes, HIV, sickle cell disease, nephrotic syndrome and minimal change disease. On microscopic histopathological analysis progressive changes seen are, foot process effacement, podocyte apoptosis, exposed GBM, capillary expansion and mesangial matrix proliferation.
Pathophysiology
Pathophysiology
There are two types of FSGS, primary FSGS and secondary FSGS, pathophysiology is discussed below:
Pathogenesis of primary FSGS
- The pathogenesis of primary or Idiopathic FSGS is not so clear.[1]
- Many studies had theorized that FSGS occurs as a consequence of effects of circulating immune activating factors on the glomerular epithelium.[1]
- The damaging role of circulating factors like the soluble urokinase plasminogen activating receptor (suPAR) on the glomerular podocytes had been suggested.[1]
- The underlying pathogenesis of FSGS is fusion or effacement of the foot processes (podocytes) of the glomeruli, with sclerosing of some parts of the glomeruli (hence the name focal segmental).
- The involvement of the permselective filtration barrier and effacement of podocyte foot processes are inevitable.
- These changes result in:[2][3][4]
- Apoptosis
- Detachment from the glomerular basement membrane (GBM)
- Subsequent podocytopenia
- Interference with slit diaphragm and its corresponding lipid raft
- Interference with actin cytoskeleton
- Interference with the GBM or with the interaction of the GBM and the podocytes
- Interference with the negative charge of podocytes
- Circulating factors implicated in the pathogenesis of primary FSGS include:
- Soluble urokinase plasminogen activating receptor (suPAR) and MicroRNAs.[1]
- suPAR is a heavily glycosylated protein that can be found in several places.[4][5][6][7]
- Cardiotrophin-like cytokine factor-1 (CLCF1)
Pathogenesis of secondary FSGS
The pathogenesis of secondary focal segmental glomerulosclerosis (FSGS) occurs due to the following factors:
- Glomerular hypertrophy and hyperfiltration, which is due to the following:[8][9]
- Various inflammatory mediators include over-expression of:[3][10][11]
Genetics
Genetics
The development of focal segmental glomerulosclerosis is the result of multiple genetic mutations such as:[12][10][13][14][15][16][17][18]
- Nephrin gene in congenital Finnish-type nephrotic syndrome – NPHS1
- Nephrin-like transmembrane gene – NEPH1
- Podocin gene – NPHS2
- CD2-associated protein (CD2AP)
- Alpha-actinin-4 gene
- Transient receptor potential cation channel – TRPC6
- Mutation in wilms tumor gene – WT1
- Mitochondrial cytopathies
Associated Conditions
Associated Conditions
Conditions associated with focal segmental glomerulosclerosis (FSGS):[19][20][21][22][23][24][25]
Microscopic Pathology
Microscopic Pathology
On microscopic histopathological analysis progressive changes seen are:[10][26]
- Foot process effacement
- Podocyte apoptosis
- Exposed glomerular basement membrane
- Capillary expansion
- Formation of synechiae
- Mesangial matrix proliferation
References
References
- β 1.0 1.1 1.2 1.3 Reiser J, Nast CC, Alachkar N (2014). “Permeability factors in focal and segmental glomerulosclerosis”. Adv Chronic Kidney Dis. 21 (5): 417β21. doi:10.1053/j.ackd.2014.05.010. PMCΒ 4149759. PMIDΒ 25168830 PMID 25168830 Check
|pmid=value (help). - β Asanuma K, Mundel P (2003). “The role of podocytes in glomerular pathobiology”. Clin Exp Nephrol. 7 (4): 255β9. doi:10.1007/s10157-003-0259-6. PMIDΒ 14712353.
- β 3.0 3.1 Fogo AB (2003). “Animal models of FSGS: lessons for pathogenesis and treatment”. Semin Nephrol. 23 (2): 161β71. doi:10.1053/snep.2003.50015. PMIDΒ 12704576.
- β 4.0 4.1 Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ; et al. (2012). “Circulating suPAR in two cohorts of primary FSGS”. J Am Soc Nephrol. 23 (12): 2051β9. doi:10.1681/ASN.2012030302. PMCΒ 3507361. PMIDΒ 23138488.
- β Rea R, Smith C, Sandhu K, Kwan J, Tomson C (2001). “Successful transplant of a kidney with focal segmental glomerulosclerosis”. Nephrol Dial Transplant. 16 (2): 416β7. PMIDΒ 11158426.
- β Ghiggeri GM, Artero M, Carraro M, Perfumo F (2001). “Permeability plasma factors in nephrotic syndrome: more than one factor, more than one inhibitor”. Nephrol Dial Transplant. 16 (5): 882β5. PMIDΒ 11328888.
- β Kemper MJ, Wolf G, MΓΌller-Wiefel DE (2001). “Transmission of glomerular permeability factor from a mother to her child”. N Engl J Med. 344 (5): 386β7. doi:10.1056/NEJM200102013440517. PMIDΒ 11195803.
- β Harris RC, Neilson EG (2006). “Toward a unified theory of renal progression”. Annu Rev Med. 57: 365β80. doi:10.1146/annurev.med.57.121304.131342. PMIDΒ 16409155.
- β Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL; et al. (2001). “Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1”. J Am Soc Nephrol. 12 (7): 1434β47. PMIDΒ 11423572.
- β 10.0 10.1 10.2 Kwoh C, Shannon MB, Miner JH, Shaw A (2006). “Pathogenesis of nonimmune glomerulopathies”. Annu Rev Pathol. 1: 349β74. doi:10.1146/annurev.pathol.1.110304.100119. PMIDΒ 18039119.
- β Hostetter TH (2003). “Hyperfiltration and glomerulosclerosis”. Semin Nephrol. 23 (2): 194β9. doi:10.1053/anep.2003.50017. PMIDΒ 12704579.
- β KestilΓ€ M, Lenkkeri U, MΓ€nnikkΓΆ M, Lamerdin J, McCready P, Putaala H; et al. (1998). “Positionally cloned gene for a novel glomerular protein–nephrin–is mutated in congenital nephrotic syndrome”. Mol Cell. 1 (4): 575β82. PMIDΒ 9660941.
- β Tryggvason K, Patrakka J, Wartiovaara J (2006). “Hereditary proteinuria syndromes and mechanisms of proteinuria”. N Engl J Med. 354 (13): 1387β401. doi:10.1056/NEJMra052131. PMIDΒ 16571882.
- β Kim JM, Wu H, Green G, Winkler CA, Kopp JB, Miner JH; et al. (2003). “CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility”. Science. 300 (5623): 1298β300. doi:10.1126/science.1081068. PMIDΒ 12764198.
- β Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O; et al. (1999). “Congenital nephrotic syndrome in mice lacking CD2-associated protein”. Science. 286 (5438): 312β5. PMIDΒ 10514378.
- β Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ; et al. (2000). “Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis”. Nat Genet. 24 (3): 251β6. doi:10.1038/73456. PMIDΒ 10700177.
- β Winn MP (2003). “Approach to the evaluation of heritable diseases and update on familial focal segmental glomerulosclerosis”. Nephrol Dial Transplant. 18 Suppl 6: vi14β20. PMIDΒ 12953036.
- β Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH; et al. (2013). “KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis”. Am J Kidney Dis. 62 (3): 403β41. doi:10.1053/j.ajkd.2013.06.002. PMIDΒ 23871408.
- β Hogan J, Radhakrishnan J (April 2013). “The treatment of minimal change disease in adults”. J. Am. Soc. Nephrol. 24 (5): 702β11. doi:10.1681/ASN.2012070734. PMIDΒ 23431071.
- β Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, Kasiske B, Liu J, Mau LW, McBean M, Murray A, St Peter W, Guo H, Gustafson S, Li Q, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, Agodoa L (January 2011). “US Renal Data System 2010 Annual Data Report”. Am. J. Kidney Dis. 57 (1 Suppl 1): A8, e1β526. doi:10.1053/j.ajkd.2010.10.007. PMIDΒ 21184928.
- β Cohen AH, Nast CC (March 1988). “HIV-associated nephropathy. A unique combined glomerular, tubular, and interstitial lesion”. Mod. Pathol. 1 (2): 87β97. PMIDΒ 3070550.
- β Ataga KI, Derebail VK, Archer DR (September 2014). “The glomerulopathy of sickle cell disease”. Am. J. Hematol. 89 (9): 907β14. doi:10.1002/ajh.23762. PMCΒ 4320776. PMIDΒ 24840607.
- β Gopalakrishnan I, Iskandar SS, Daeihagh P, Divers J, Langefeld CD, Bowden DW, Hicks PJ, Rocco MV, Freedman BI (February 2011). “Coincident idiopathic focal segmental glomerulosclerosis collapsing variant and diabetic nephropathy in an African American homozygous for MYH9 risk variants”. Hum. Pathol. 42 (2): 291β4. doi:10.1016/j.humpath.2010.07.016. PMCΒ 3022108. PMIDΒ 21074826.
- β Hanaoka H, Hashiguchi A, Konishi K, Kuwana M, Takeuchi T (May 2015). “An unusual association between focal segmental sclerosis and lupus nephritis: a distinct concept from lupus podocytopathy?”. CEN Case Rep. 4 (1): 70β75. doi:10.1007/s13730-014-0142-1. PMCΒ 5411626. PMIDΒ 28509272.
- β Brown EJ, Pollak MR, Barua M (May 2014). “Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing”. Kidney Int. 85 (5): 1030β8. doi:10.1038/ki.2014.48. PMCΒ 4118212. PMIDΒ 24599252.
- β Reidy K, Kaskel FJ (March 2007). “Pathophysiology of focal segmental glomerulosclerosis”. Pediatr. Nephrol. 22 (3): 350β4. doi:10.1007/s00467-006-0357-2. PMCΒ 1794138. PMIDΒ 17216262.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Ali Poyan Mehr, M.D. [2]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [3], Manpreet Kaur, MD [4], Cafer Zorkun, M.D., Ph.D. [5], Olufunmilola Olubukola M.D.[6]
